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Abstract: While investigative ophthalmologists access peer-reviewed journals as part of their 
daily routine, and while they regularly visit scientiﬁ  c congresses, they rarely peruse patent 
documents as an information source. Among the reasons for this negligence are the incompat-
ibility of patent search algorithms with those known from journal databases, a legalistic and 
frequently redundant language, and misconceptions about the nature of the patenting system. 
Here we present key data and analyses from the ophthalmology module of a patent database 
system that we are developing to address some of these problems. We show that international 
patent applications consistently reﬂ  ect developer interest in the ocular drug and diagnostics 
ﬁ  eld; that they are technically focused lead indicators of developments that frequently feature 
in peer-reviewed patenting only much later; and that patenting targets are well aligned with the 
unmet therapeutic needs of populations in industrialized countries. Most applications (74%–78% 
in years since 2006) are supported with experimental data, and most (on average, 80%–90%) 
faced at least one objection to patentability during their initial stage of examination. In contrast 
to the peer-reviewed scenery that is highly diverse, the corresponding patenting arena shows a 
pronounced focus on the United States.
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Introduction
Ophthalmologists, like most other medical specialists, obtain scientiﬁ  c information 
mainly from two sources: from the peer-review literature, and from scientiﬁ  c con-
gresses that cover their specialty. This provides an impressive amount of information: 
MEDLINE covers more than 50 peer-reviewed periodicals which exclusively focus 
on ocular medicine, and there are about 100 additional journals which have a broader 
scope or a different focus but which regularly publish papers on eye medicine. The 
number of substantial international congresses that compete for the time and attention of 
research ophthalmologists amounts to at least a dozen in any given year. However, there 
is another extremely important source of scientiﬁ  c and technical information – patent 
documents – which is utilized to a much lesser degree if at all, even though its basic 
data sources are universally accessible without charge.
There are several reasons why most researchers hardly ever peruse intellectual 
property documents to an extent comparable to their use of the peer-reviewed litera-
ture. First, the primary purpose of a patent is to unequivocally establish the applicant’s 
priority rights to the claimed invention. Scientists and clinicians are not accustomed to 
the legalistic language of intellectual property documents, which makes the extraction 
of information difﬁ  cult for them. Second, many aspects of the criteria for novelty, 
nonobviousness and utility as used by the patent system differ substantially from Clinical Ophthalmology 2009:3 104
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what the scientiﬁ  c community believes these terms stand for. 
Third, and most importantly, public patent databases cannot 
be meaningfully searched using intuitive standardized and 
structured keywords in the way MEDLINE can be searched 
using MESH terms. They have their own hierarchically 
nested document classiﬁ  cation system that is incomprehen-
sible to anybody who is not a patent specialist. As a result, 
the knowledge contained in the “patent information space” 
is largely inaccessible to the average researcher or clinician, 
even though the raw data is available online.
This is an extremely wasteful situation because patent 
documents provide a perspective of applied science and 
technology that is substantially different from what is offered 
by peer-reviewed papers, which are primarily written to com-
municate new insights and to advance basic understanding.
This general dilemma fully translates to research, devel-
opment, and practice of clinical ophthalmology, where the 
specialist journals rarely cite patents as scientiﬁ  c references. 
There is no reasonably quick and easy way to search for patent 
documents of substantial ophthalmological content that 
would return a set of data that is highly focused and complete. 
If ocular research periodicals speciﬁ  cally address patenting 
at all, it is to discuss controversial uses of the system,1,2 or 
to investigate the interaction of sponsorship with research.3,4 
Systematic reviews of ocular patenting activity are usually 
published in journals that are focused either on patenting5–9 
or on general drug discovery and development.10,11
We are currently developing a database system that is 
designed to make patent information more accessible to sci-
entists and clinicians in select specialties; one of its modules 
focuses on ophthalmology. Here we present an analysis of the 
key features of international ocular patenting that highlights 
its potential relevance for the development of therapeutic and 
diagnostic products.
Methods
Using internally optimized and validated search algorithms 
supplemented with manual searches, we have exhaustively 
identiﬁ  ed patents centered on ocular subjects from the Patent 
Convention Treaty (PCT) public database PatentScope(R).12 
A document was included in our collection if it had ocular 
drugs, drug delivery, tissue culture, gene therapy, or diag-
nostics (including biomarkers) as at least one of its major 
subjects, or if it had these ocular uses as a secondary sub-
ject but reported experimental data that directly supported 
such applications. The time frame for publication dates 
was the period between January 1986 and June 2008. 
Document key data were captured in a local SQL database. 
Document content was indexed according to the Medical 
Subject Headings (MeSH)-controlled vocabulary13 which 
MEDLINE employs for indexing articles, and textual content 
was processed for metadata.
While the inclusion of substantial experimental data in 
patent applications is not mandatory (such data can be sub-
mitted during the examination process up to one year after 
ﬁ  ling the patent), their presence in the published version is 
obviously crucial for the document’s utility as a source of 
scientiﬁ  c information. As one of its sets of metadata, our 
database ﬂ  ags each document for the presence or absence 
of such substantial experimental data that support one or 
more of the claims.
PCT patent documents are either published together with 
an international search report (ISR), or this report is published 
separately within the subsequent months (unless the applica-
tion is retracted or fails to meet the formal criteria). ISRs are 
standardized patent ofﬁ  ce replies where the examiner cites the 
references on which the initial rejection of individual claims 
for alleged lack of novelty or inventiveness are based. This 
amounts to the approximate equivalent of the initial stage 
of an open peer review. Critical rejections are of two types: 
type X, which is based on a single earlier document, and 
type Y which is based on the content of two or more docu-
ments considered together. The combined number of X and 
Y rejections can be considered a surrogate measure of the 
novelty and inventiveness of the claimed invention as judged 
by the examiner. For each document for which an ISR was 
available we have captured the number and type distribution 
of such rejections.
Results
Time proﬁ  le of applications, 1986–2008
A total of 2,967 PCT ophthalmology documents were identi-
ﬁ  ed. The annual count of published applications increased 
dramatically and almost consistently during the 22.5 year 
period investigated, from 10 documents each in 1986 and 
1987 to 333 in 2007. Based on the data from the ﬁ  rst half 
of the year we expect almost 400 patents to be published 
in 2008 (Figure 1). However, most of this growth reﬂ  ects 
the steep increase in the overall number of PCT documents 
published by the World Intellectual Property Organization. 
The fractional share of “predominantly ocular” documents 
meeting our inclusion criteria – a surrogate measure for the 
relative interest in ophthalmology patenting – exhibited far 
less variation (between 0.13% and 0.31% of all published 
PCT documents; Figure 2). An initial increase until 1995 was 
followed by a pronounced drop that was reversed in 2000. Clinical Ophthalmology 2009:3 105
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Subsequently there has been a slow but steady increase in 
relative interest, and the ﬁ  gure has remained constant at 0.22% 
for the most recent 2005–2007 period. A deeper exploratory 
analysis with temporal linkage to the peer-review literature 
(data not shown) suggests that the relative peak period which 
is evident for the 1993–1994 period might have been a pre-
cursor to the surge in research attention to ophthalmology 
triggered by the discovery of the role of vascular endothelial 
growth factor (VEGF) in retinal disease.
Language and origin of applications, 
1999 to mid-2008
Of the 2199 applications published between January 1999 
and June 2008, 1821 (82.8%) were in English, and therefore 
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Figure 1 Annual count of ocular drug, diagnostics and cell culture PCT patent applications included in the database, 1986–2007.
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
0.00%
0.05%
0.10%
0.15%
0.20%
0.25%
0.30%
0.35%
Figure 2 Percentage of ocular drug, diagnostics and cell culture patent applications expressed as percentage of all PCT applications published in the respective year, 
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immediately accessible to virtually the entire community 
of research ophthalmologists. The second most common 
language was Japanese, at 12.6%. The other languages 
allowed by the PCT system were rarely used; German, 
French, and Spanish accounted only for 1.9, 1.2 and 1.0%, 
respectively and there were only ﬁ  ve applications made in 
Russian and three in Chinese.
Analyzing the priority countries (ie, the countries were 
the initial patent ﬁ  ling was submitted) for all documents 
published since 1986, we found the following distribution: 
69.8% came from the United States; 17.0% originated from 
individual European countries or from the European Patent 
Organization; 12.3% came from Japan; and only 0.9% came 
from elsewhere. In recent years the balance has shifted 
towards a further strengthening of the United States’ position 
(data not shown) because major European patentees in the 
ophthalmology drugs and diagnostics scenery have merged 
with US companies. (For example, Pharmacia – which used 
to ﬁ  le ﬁ  rst in Sweden – has been absorbed into Pﬁ  zer.)
Presence of supporting data and pattern 
of initial claim rejections
The results of this dual analysis are presented in Table 1. 
Since 1999 the percentage of PCT ophthalmology docu-
ments that present substantial experimental data in support 
of their claims has varied between 63% and 84% but has 
remained almost constant (in the range of 74%–78%) for 
the applications published since January 2006. The number 
of published applications without “X” or “Y” rejections 
(ie, those which received an tentative “clean bill of 
patentability” during initial examination) remained relatively 
constant (10%–19%) from 1999 to 2003, and then began 
to ﬂ  uctuate. The low ﬁ  gure for 2007 is not due to a higher 
number of yet unpublished search reports but reﬂ  ects a real 
decrease in expressed objections.
Targets of recent ocular patenting
An analysis of the patenting targets for the most recent two-
year publishing period with complete information (October 
2006 to September 2007) revealed the pattern presented in 
Figure 3. Among the patent documents that had a single or 
predominant application focus, retinal diseases and glaucoma 
headed the list of target conditions, followed by dry eye 
syndrome and the group comprised of lens and refractive 
disorders. About one ﬁ  fth of all applications dealt with ocular 
drug delivery technologies.
Case study in ocular patenting: 
iontophoretic drug delivery
Since our database features a MeSH term index in addition 
to patent codes, it allows identical parallel searches using 
MEDLINE conventions. To illustrate how ophthalmological 
patenting can supplement or anticipate information published 
in academic journals, we have conducted a search for all 
international patent documents published between 1986 and 
June 2008 for which ocular iontophoretic drug delivery is 
the primary subject of the invention.
The retrieved set of 18 PCT documents revealed no 
dedicated document for ocular iontophoresis prior to 
August 1999. (Although several earlier applications men-
tion that the subject drugs of the respective invention can be 
administered to the eye by iontophoresis, they do not point 
out workable examples.) This is quite surprising because 
United States national patents with a main focus on this 
subject go back to at least 1950, and the pertinent peer-
reviewed literature can be traced back even to the 1910s. 
However, by the 1990s the actual use of this technology had 
diminished considerably and few clinical ophthalmologists 
were familiar with it.
In 1999 the business development arm of the Hebrew 
University of Jerusalem published the ﬁ  rst international 
patent application which claimed a iontophoretic drug 
delivery device employing a hydrogel probe.14 It took ﬁ  ve 
more years for this system to appear in the peer-reviewed 
literature.15 But developers had already taken note and from 
2002 onward a steady stream of patent applications were pub-
lished. The ﬁ  rst ones came from the iontophoresis specialist 
company Iomed, Inc., (Salt Lake City, UT, USA), covering 
what soon became known as the OcuPhorTM device, and 
applications of this device to deliver vascular endothelial 
Table 1 Selected metadata for ocular drug, tissue culture and 
diagnostic patents, 1999–2008
Year of publication Applications with 
experimental data
Applications without 
examiner objections
1999 69.9% 15.9%
2000 84.4% 10.4%
2001 72.3% 18.6%
2002 62.9% 18.5%
2003 64.5% 18.9%
2004 73.2% 26.8%
2005 68.5% 16.7%
2006 73.8% 21.3%
2007 72.6% 7.8%
2008 (Jan–Jun) 78.1% Not meaningfully 
calculable at presentClinical Ophthalmology 2009:3 107
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growth factor (VEGF) inhibitor aptamers,16 interferons,17 
methotrexate,18 and steroids19 to the eye. A clinical study 
published in 2003 reported the ﬁ  rst clinical data obtained with 
this device.20 While ocular iontophoresis of the corticoste-
roid, dexamethasone had been reported in the peer-reviewed 
literature as early as 1989,21 methotrexate delivery featured 
there only in 2007.22 For interferons no ocular iontophoretic 
delivery has been reported in the nonpatent literature even 
until today. However, applications involving oligonucleotide 
aptamers including those blocking VEGF actions appeared 
almost at the same time as the respective Iomed patent 
application, in a paper by the French research organization 
INSERM23 which had been preceded by a PCT patent docu-
ment jointly ﬁ  led by Optis France (Paris) and INSERM.24 
Optis (which later became Eyegate Pharma) followed up 
with several additional applications outlining the design of 
its various devices.25–30 While Iomed’s ocular iontophoresis 
developments came to an end in 2007 when it was acquired 
by a medical device company, another industrial player from 
Salt Lake City, Aciont, Inc., had emerged with its ﬁ  rst patent 
application including data and claims for ocular iontophoresis 
in 2004.31 Later applications addressed devices for the deliv-
ery of steroid-sparing immunosuppressive agents (including 
monoclonal antibodies)32 and two new types of devices.33,34 
The inventor team has published peer-reviewed papers on the 
general subject,35,36 but no clinical studies have been reported 
from Aciont so far.
There are only two other PCT patent assignees in 
this field, both of whom produced single documents. 
One came from Ceramatec, Inc.37 (another Salt Lake 
City company), and one from the University of South 
Florida.38 In both cases the inventors have published on 
iontophoretic drug delivery, but only in ﬁ  elds other than 
ophthalmology.
Discussion
For reasons of research capacity, our database of international 
patent applications in ophthalmology does not yet cover 
medical devices that are not related to drug delivery (such 
as intraocular lenses or glaucoma shunts unless they elute 
drugs, or surgery and diagnostic equipment such as lasers or 
cameras). However, in its present state – with coverage of 
drugs, gene therapy, tissue- and cell-based technologies, and 
diagnostics from 1986 to present – it has already revealed 
indications of the value which a user-friendly database on 
ocular patenting that is tightly selected, comprehensive, and 
annotated for content would have as a scientiﬁ  c information 
resource for the clinical ophthalmology ﬁ  eld.
Using the MEDLINE-compatible index feature we were 
able to show, in a case study of patent applications centered 
on iontophoretic drug delivery to the eye, that these docu-
ments can contain technical information of high potential 
relevance to clinical development. We have also shown that 
much of this information emerges in peer-review papers only 
later, or in many cases not at all. Even where information is 
apparently duplicated it is presented in a different context 
and from a different perspective, making it a valuable asset 
for researchers and developers.
Figure 3 Target indications for ocular drug, diagnostics and cell culture patent applications, October 2006 to September 2007.Clinical Ophthalmology 2009:3 108
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Approximately three quarters of all international 
applications from our database include experimental data. At 
least for the ocular drug and diagnostic ﬁ  eld, the frequently 
expressed opinion that patents tend to make exhaustive claims 
without offering hard data does not seem broadly valid. Even 
in those cases where such data support only some of the 
claims, or where they would not be considered sufﬁ  ciently 
elaborate or precise by the peer reviewers for an academic 
paper, they are of considerable value in the technical context 
of the application. Frequently they are among the ﬁ  rst hard 
data that become available in reproducible form. In another 
analysis we show that patent examiners tend to be quite rigid 
and thorough in their initial rejections, with only a small 
fraction of ocular applications not drawing formal objections 
at the start of the review process. We have not investigated to 
which degree the applicants have overcome such opposition 
in the subsequent national phases of patenting.
As has recently been shown for drug development efforts 
targeting Alzheimer’s disease,39 patenting activity is a leading 
indicator of developer interest in any given competitive 
segment of the medical sciences. We have provided a prelimi-
nary analysis for the ocular drugs and diagnostics segment 
that suggests that this attention, while largely consistent over 
recent times, might also reﬂ  ect developer responses to new 
insights that are believed to have the potential to result in 
marketable products.
Our analysis of patenting targets from a recent 2-year 
period reveals that the distribution of disease targets closely 
resembles the relevance of the respective disorders for eye-
sight problems in the industrialized nations. It is no surprise 
to see that typical eye diseases of developing countries are 
hardly addressed in patenting since their effective treatment 
would in most cases not require patentable innovation.
Our ocular patent database still has considerable limita-
tions. International patent applications that are published in 
languages other than English are not yet properly represented 
in our content index. We are currently working on identify-
ing and including the English versions of such documents, 
which become accessible if and when the applicant ﬁ  les 
the corresponding US and/or European patent applications. 
Finally, because our database is centered on international PCT 
applications it does not yet contain documents for which no 
PCT ﬁ  lings were made. A pilot investigation that we have 
undertaken for the year 2005 indicates that the exclusion of 
US-only patents might have caused 10%–15% of the total ocu-
lar patents to be missed in the analysis. This factor is likely to 
play a signiﬁ  cantly larger role in the years prior to about 1995, 
ie, in the time before the ophthalmology developer community 
utilized the PCT ﬁ  ling system as intensely as it does today. 
Future expansions of our database will also include applica-
tions made only in the United States and Europe.
In summary, we are in the process of building a database 
covering substantially all inventive activity in ophthalmology 
that has led to patent applications in the major intellectual 
property systems. This will provide a unique resource for 
developers in the ﬁ  eld, amounting to the opening of a “third 
space of information” (peer-review literature and scientiﬁ  c 
congresses being the ﬁ  rst two dimensions). Further plans 
include features such as interfaces with public databases and 
integrated visualization of query results.
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